Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

Bullboard Posts

Comment by Francine01on Jan 19, 2018 4:49pm

159 Views

Post# 27397754

RE:RE:RE:RE:RE:Short and distort!

cat2cat wrote: I always thought they had a 4 month hold same as a pp. Wonder why they did it this way

Acasti had no choice, since the prospectus was filed in the US and some canadian brokers / investors complained that could not participate because it was only Us, so Acasti did a private placement in Canada which required a 4 month period. I personally participated, aspart of the 1.5M share issued with the 4 months holding period... which is really frustrating, but we didn't had any choice.

Bullboard Posts

With purification plant producing, helium firm focuses on exploration